We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

66 hedge funds and large institutions have $245M invested in Xenon Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 3

69% more capital invested

Capital invested by funds: $145M → $245M (+$100M)

36% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 14

22% more funds holding

Funds holding: 54 → 66 (+12)

9.87% more ownership

Funds ownership: 62.44% → 72.3% (+9.9%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
66
Holders Change
+12
Holders Change %
+22.22%
% of All Funds
1.3%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
15
Increased
19
Reduced
14
Closed
3
Calls
$253K
Puts
–
Net Calls
+$253K
Net Calls Change
+$252K

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$6.57M
2
NMC
NEA Management Company
Maryland
+$4.1M
3
ACM
Aquilo Capital Management
California
+$2.26M
4
ACP
Acuta Capital Partners
California
+$2.26M
5
BI
BVF Inc
California
+$2.18M

Top Sellers

1
BlackRock
BlackRock
New York
-$2.31M
2
DCM
DAFNA Capital Management
California
-$861K
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$728K
4
Squarepoint
Squarepoint
New York
-$579K
5
AA
ALPS Advisors
Colorado
-$463K
Name Holding Trade Value Shares
Change 		Change in
Stake
OAM
51
Oxford Asset Management
United Kingdom
$165K +$132K +12,553 New
Invesco
52
Invesco
Georgia
$163K +$19.6K +1,865 +18%
SACTSONJ
53
Supplemental Annuity Collective Trust (SACT) of New Jersey
New Jersey
$144K – – –
IVM
54
InterWest Venture Management
California
$109K – – –
Bank of Montreal
55
Bank of Montreal
Ontario, Canada
$66K -$12.6K -1,198 -19%
TRCT
56
Tower Research Capital (TRC)
New York
$65K +$21.1K +2,004 +67%
Morgan Stanley
57
Morgan Stanley
New York
$53K -$38.4K -3,653 -47%
Deutsche Bank
58
Deutsche Bank
Germany
$41K +$33K +3,134 New
Bank of America
59
Bank of America
North Carolina
$34K +$27.5K +2,618 New
CFGS
60
Concourse Financial Group Securities
Alabama
$26K +$10.5K +1,000 +100%
UBS Group
61
UBS Group
Switzerland
$23K +$5.49K +522 +42%
Citigroup
62
Citigroup
New York
$18K +$7.09K +674 +99%
CG
63
Cutler Group
California
$12K +$10.2K +969 New
LTFS
64
Ladenburg Thalmann Financial Services
Florida
$10K +$7.89K +750 New
Wells Fargo
65
Wells Fargo
California
$4K – – –
Barclays
66
Barclays
United Kingdom
$2K -$2.28K -217 -57%
BlackRock
67
BlackRock
New York
– -$2.31M -256,667 Closed
AA
68
ALPS Advisors
Colorado
– -$463K -51,356 Closed
Daiwa Securities Group
69
Daiwa Securities Group
Japan
– -$1K -165 Closed
1 2
3

XENE Hedge Fund Activity: Q4 2019 in Review

66 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2019, worth a combined $245M — up 69% from $145M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new XENE positions and 3 closed out — a net gain of 12 holders — while 19 added to existing stakes and 14 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $6.57M. The largest seller was BlackRock, exiting entirely with an estimated $2.31M sold.

  • 66 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2019, up from 54 in Q3 2019.
  • Funds reported $245M of Xenon Pharmaceuticals stock for Q4 2019, up 69% quarter-over-quarter.
  • 15 funds opened new Xenon Pharmaceuticals positions in Q4 2019 and 3 closed out, a net change of +12 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2019 was Adage Capital Partners, an estimated $6.57M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2019 was BlackRock, an estimated $2.31M sold.

Based on aggregated 13F filings for Q4 2019.